What Is the Anti-CCP Ab IgG/IgA Test and Its Purpose?

The anti-CCP Ab IgG/IgA test measures antibodies your immune system produces against proteins that have undergone a chemical change called citrullination. Its primary purpose is to help diagnose rheumatoid arthritis, a chronic autoimmune disease that attacks the joints. The test is valued because it can flag RA with high confidence, often years before joint damage becomes visible on X-rays, and it outperforms the older rheumatoid factor test in distinguishing RA from other conditions that cause joint pain. But the IgG and IgA components tell slightly different stories about what is happening in your body, and the test’s usefulness extends well beyond a simple yes-or-no diagnosis.

What the Test Actually Measures

Your body naturally contains proteins with an amino acid called arginine. In certain conditions, an enzyme converts that arginine into a different amino acid called citrulline. This process, citrullination, happens in everyone to some degree. In people who go on to develop RA, the immune system mistakenly treats these citrullinated proteins as threats and produces antibodies against them. These are called anti-citrullinated protein antibodies, or ACPAs. The anti-CCP test uses synthetic cyclic citrullinated peptides as bait to detect those antibodies in a blood sample.

The test has gone through several generations. The first-generation assay had poor sensitivity and is no longer widely used. Second-generation (CCP2) and third-generation (CCP3) assays improved both sensitivity and specificity, though evidence is mixed on whether CCP3 truly outperforms CCP2 for established RA.¹ Most clinical labs today run a CCP2 or CCP3 assay. The standard version detects IgG antibodies. Some labs offer an expanded panel that also captures IgA anti-CCP antibodies, which is where the “IgG/IgA” label comes from.

How Accurate Is the Test

Anti-CCP testing is best known for its specificity, which generally falls between 90% and 95%. That means if the test is positive, there is a very high chance the person actually has RA rather than some other condition. Sensitivity is more modest, typically in the range of 60% to 80%, which means it misses some people who do have the disease.² A negative result does not rule out RA. That asymmetry matters: a positive test is a strong signal, a negative test is not an all-clear.³

Sensitivity improves when anti-CCP is paired with rheumatoid factor testing. RF on its own is less specific because it shows up in many other inflammatory conditions, infections, and even healthy older adults. But when both tests come back positive, the likelihood of RA jumps considerably. One primary-care study found that implementing a “double-positive” testing strategy cut unnecessary rheumatology referrals from about 22% down to roughly 8%, without increasing the number of missed diagnoses.⁴ Patients who are positive for both markers also tend to have higher disease activity and higher levels of inflammatory markers than people who test positive on only one.⁵

Why IgA Is Tested Alongside IgG

IgG anti-CCP antibodies are the workhorse of the test. They are the most abundant isotype in RA patients and the strongest predictor of future disease. IgA anti-CCP antibodies are less common but add a different layer of information. In blood samples collected before people even develop RA symptoms, IgG and IgA anti-CCP both appear years in advance, with IgG showing up slightly earlier and at higher levels. Both are far more predictive of future RA than the rarer IgM isotype.⁶

IgA antibodies are particularly interesting because they are the immune system’s front-line defenders at mucosal surfaces, the linings of your lungs, gut, and mouth. Research on people who carry anti-CCP antibodies but have not yet developed joint symptoms has found elevated IgA-producing immune cells in their blood, suggesting that the autoimmune process may start at a mucosal site rather than in the joints themselves.⁷ This fits with the growing understanding that smoking and gum disease, both of which irritate mucosal tissue, are linked to RA risk.

Clinically, adding IgA anti-CCP to the standard IgG test does not appear to catch additional RA patients who would otherwise be missed. However, patients who are IgA-positive seem to respond less well to certain biologic medications, specifically anti-TNF drugs, compared with patients who only carry IgG antibodies.⁸ That prognostic angle is probably the main practical reason a clinician would order the combined IgG/IgA panel rather than just a standard anti-CCP test.

Predicting How Aggressive the Disease Will Be

Beyond diagnosis, anti-CCP results carry prognostic weight. A positive test at the time of diagnosis is associated with more joint erosion over time. A meta-analysis pooling data from multiple studies found that anti-CCP-positive patients had roughly five times the odds of developing joint erosions compared with anti-CCP-negative patients.⁹ Individual studies have confirmed that this correlation is visible in both early and established disease, and that anti-CCP positivity outperforms RF as a predictor of a more aggressive course over several years.¹⁰ Anti-CCP-positive patients at diagnosis had greater joint damage scores than anti-CCP-negative patients, even when RF levels did not differ between the groups.¹¹

The level of antibodies matters too, not just whether they are present. Higher anti-CCP concentrations predict a shorter time from first autoantibody appearance to actual RA onset.¹² This is why many rheumatologists pay attention to the actual titer rather than treating the result as a binary positive or negative.

Antibodies Before Symptoms

One of the most striking findings about anti-CCP is that it can appear in the blood years before a person ever feels joint pain. Studies of stored blood samples from military personnel and blood donors who later developed RA found that anti-CCP antibodies were detectable well in advance of symptom onset. In no cases did joint symptoms appear before the antibodies did.¹³ Concentrations of IgG and IgA anti-CCP both climbed steadily in the years leading up to diagnosis, with the steepest rise in the final year or two before symptoms.⁶

This has practical implications. Researchers are now exploring whether testing at-risk people, such as close relatives of RA patients, could allow earlier treatment that prevents irreversible joint damage. An early economic analysis of targeted anti-CCP screening in primary care found that using a prediction model to choose who gets tested more than halved the number of people who need to be tested to identify one at-risk patient, and lowered the cost per referral substantially compared with testing everyone.¹⁴ Separate cost-effectiveness research has concluded that using anti-CCP in the workup of patients with unexplained joint inflammation is likely cost-effective compared with relying on clinical criteria alone, especially when you account for the downstream savings from earlier treatment.¹⁵

What a Positive Test Means When You Do Not Have RA

Anti-CCP is highly specific for RA, but not perfectly so. Small percentages of people with other autoimmune and rheumatic diseases also test positive. A study of over 1,100 patients across multiple rheumatic conditions found anti-CCP in about 70% of RA patients but also in roughly 10% to 21% of patients with psoriatic arthritis, Sjögren syndrome, lupus, mixed connective tissue disease, and juvenile arthritis.¹⁶ Fewer than 3% of patients with non-inflammatory conditions tested positive, which reinforces the test’s specificity for autoimmune joint disease even when it is not always RA specifically.

In Sjögren syndrome, anti-CCP positivity was closely linked to the presence of joint inflammation, with patients who tested positive having significantly higher odds of synovitis.¹⁷ Similarly, anti-CCP-positive lupus patients were more likely to have experienced arthritis, and erosive joint damage was far more common among them.¹⁸ The pattern suggests that anti-CCP positivity in these other diseases may mark a subset of patients whose joint involvement resembles RA more closely than the typical presentation of their primary condition. For clinicians, this finding can guide decisions about whether to treat the joint disease more aggressively.

What If the Test Is Negative but You Still Have RA

Roughly 20% to 40% of people with RA test negative for anti-CCP. This is sometimes called “seronegative RA,” though some of those patients will still be positive for RF. Being seronegative does not mean you do not have the disease; it means diagnosis relies more heavily on imaging and clinical evaluation.

Researchers have been searching for alternative antibodies that could help in seronegative cases. Anti-carbamylated protein antibodies, or anti-CarP, have attracted attention. In one single-center evaluation, about 17% of anti-CCP-negative RA patients were positive for anti-CarP, which could help build diagnostic confidence in that harder-to-classify group.¹⁹ Anti-CarP testing is not yet standard in most labs, but it represents one promising avenue for closing the diagnostic gap.

Reading Your Results and Threshold Cutoffs

Most labs report anti-CCP results in units per milliliter, with a threshold above which the test is considered positive. The most common manufacturer-suggested cutoff is around 5 U/mL for CCP2 assays. At that cutoff, specificity tends to be very high but sensitivity suffers. One study found that using a lower threshold of 2 U/mL roughly doubled the sensitivity from 28% to 51% while keeping specificity at 80%.¹² Different labs and assay manufacturers use slightly different cutoffs, so your result needs to be interpreted relative to the reference range on your specific report.

A weakly positive result is less definitive than a strongly positive one. Some clinicians will repeat the test a few months later or add RF testing to clarify. A strongly positive result in someone with joint symptoms and morning stiffness, especially combined with a positive RF, is about as clear a serological signal as you will get for RA.

Tracking Treatment Response

Anti-CCP was originally conceived as a diagnostic test, but there is growing evidence that changes in antibody levels over time reflect how well treatment is working. In patients treated with the biologic drug adalimumab, anti-CCP levels dropped significantly over 24 weeks, but only in those who were actually responding to the medication. Patients who did not respond showed no meaningful change.²⁰ A similar pattern was observed with etanercept, another biologic. After three months of treatment, anti-CCP levels fell by an average of about 31%, and the drop correlated with improvements in disease activity and swollen joint counts.²¹

The clinical use of serial anti-CCP levels for treatment monitoring is not yet standardized. Most rheumatologists still rely primarily on clinical measures like joint tenderness, swelling, and inflammatory blood markers to gauge treatment response. But the finding that anti-CCP declines track with real clinical improvement suggests that serial testing could become part of routine follow-up, especially for patients on biologics.²²

Smoking, Gum Disease, and Why They Matter for This Test

The connection between RA and smoking has been recognized for decades, but anti-CCP testing has helped clarify why. Smoking irritates lung tissue and promotes citrullination of proteins in the airways, which can trigger the production of the very antibodies the test detects. This effect is amplified in people who carry certain genetic risk factors, specifically a set of gene variants known as the shared epitope on the HLA-DRB1 gene. Certain versions of these alleles confer a fivefold higher risk of developing anti-CCP antibodies, and the combination of these alleles with smoking creates a multiplied risk that neither factor produces alone.²³ In people who already carry these alleles and test positive for anti-CCP, the shared epitope is associated with higher antibody levels, essentially acting as an amplifier of the autoimmune response.²⁴

Periodontal disease, particularly infection with a bacterium called P. gingivalis, follows a parallel logic. This bacterium produces its own citrullinating enzyme, which may trigger anti-CCP production by introducing citrullinated proteins at the gum line. In a study comparing anti-CCP-positive at-risk individuals (no arthritis yet) with healthy controls, the at-risk group harbored significantly more P. gingivalis even at gum sites that appeared clinically healthy.²⁵ Interestingly, smoking may dampen the immune response to the bacterium itself while still independently elevating anti-CCP levels. Healthy smokers without gum disease had anti-CCP levels several times higher than healthy non-smokers.²⁶ Both pathways reinforce the idea that the autoimmune process behind RA often begins at mucosal surfaces and migrates to the joints later.

Anti-CCP in Children With Joint Disease

Juvenile idiopathic arthritis is the umbrella term for chronic joint inflammation in children, and it is a different entity from adult RA in many respects. Anti-CCP testing has a more limited but still meaningful role in this population. Positivity tends to cluster among children with RF-positive polyarticular JIA, the subtype that most closely resembles adult RA.²⁷ In these children, anti-CCP levels correlate with disease activity and radiographic damage, meaning a positive test can help identify kids who are likely to have a more erosive course.²⁸

A longer-term study found that anti-CCP, along with other autoantibodies, was associated with joint damage assessed eight years after JIA onset, though not with ongoing active disease at that follow-up point.²⁹ The implication is that anti-CCP marks cumulative damage risk over the long run, even in children whose disease eventually quiets down clinically. Pediatric rheumatologists do not rely on anti-CCP as a first-line diagnostic tool for most forms of JIA, but in the polyarticular RF-positive subset it provides genuinely useful prognostic information.

Where the IgA Component May Reshape Testing

The mucosal-origin theory of RA, bolstered by IgA findings, has started to shift how researchers think about prevention. If the autoimmune process begins in the lungs or gums rather than the joints, interventions aimed at those mucosal sites, such as smoking cessation, periodontal treatment, or even mucosal-targeted immune therapies, could theoretically interrupt the chain before joints are ever affected. This is speculative territory, and no clinical trial has yet demonstrated that treating gum disease prevents RA. But the presence of IgA anti-CCP antibodies in at-risk individuals provides a measurable biomarker for identifying who might benefit from such early intervention strategies.

The observation that IgA anti-CCP positivity predicts a weaker response to anti-TNF biologics also has practical consequences for treatment selection. If your test shows elevated IgA alongside IgG, your rheumatologist might consider starting with a different class of biologic or monitoring your response more closely in the early months of therapy. This kind of antibody profiling is still evolving, and no guidelines currently mandate different treatment choices based on isotype. But the evidence is building toward a more personalized approach where the specific flavor of your anti-CCP response influences which drug you try first.